ClinicalTrials.gg
Active, not recruitingNCT06993779Updated May 29, 2025

Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Upper Tract Urothelial Carcinoma

An observational study in UTUC, sponsored by Mingzhao Xiao. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Mingzhao Xiao · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,000
Sex
All
01

Study summary

Upper Tract Urothelial Carcinoma (UTUC), characterized by its anatomical complexity and often aggressive clinical behavior, presents substantial difficulties in accurate diagnosis and reliable prognostication. The stratification of postoperative survival utilizing radiomics features derived from imaging and characteristics from whole slide images could prove instrumental in guiding therapeutic decisions to enhance patient outcomes. In this research, our objective is to construct a deep learning-based prognostic-stratification system designed for the automated prediction of overall and cancer-specific survival in individuals diagnosed with UTUC.

Read the detailed description

Upper Tract Urothelial Carcinoma (UTUC) can be challenging to accurately diagnose and its course difficult to predict, as the disease manifestations and aggressiveness can differ significantly among individuals. This research seeks to create an innovative system employing artificial intelligence to process patient data, encompassing images from diagnostic scans and surgical pathology slides. This system would then be capable of automatically forecasting a patient's overall survival and their specific likelihood of surviving UTUC. Such insights could empower clinicians to tailor more effective treatment strategies for each individual patient.

02

Conditions studied

  • UTUC
03

In context

Lead sponsor

Mingzhao Xiao is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We included patients who had surgery only or who had neoadjuvant chemotherapy before surgery. We excluded patients with a postoperative diagnosis of non-urothelial carcinoma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Upper Tract Urothelial Carcinoma (UTUC) who had radical nephroureterectomy (RNU).
  • Contrast-enhanced CT scan (e.g., CT urography) less than two weeks before surgery.
  • Complete CT image data and clinical data.
  • Complete whole slide image data.

Exclusion criteria

Exclusion Criteria:

  • Patients with a postoperative diagnosis of non-urothelial carcinoma.
  • Poor quality of CT images and/or whole slide image data.
  • Incomplete clinical and follow-up data.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • AI-UTUC

    Patients with Upper Tract Urothelial Carcinoma (UTUC) who underwent radical nephroureterectomy (RNU)

    Other: Deep learning system for prognostication prediction in upper tract urothelial carcinoma

Interventions

  • OtherDeep learning system for prognostication prediction in upper tract urothelial carcinoma

    develop and validate a deep learning system for prognostication prediction in upper tract urothelial carcinoma based on CT radiomics and whole slide images.

06

What researchers measure

Primary outcomes

  1. Overall survival

    the time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off.

    Time frame: up to 10 years

Secondary outcomes

  1. Recurrence free survival

    the time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored

    Time frame: up to 10 years

07

Study locations

1 site
  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, chongqing, chongqing 400016 Recruiting
    Chongqing, 400016, China
08

References and documents

Individual participant data

Plan to share: No — The datasets analyzed during the current study are not publicly available due to the privacy of patients but are available from the corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jun 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Jun 1, 2025
CompletionEst.
Nov 1, 2025
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06993779
Lead sponsor
Mingzhao Xiao
Responsible party
Mingzhao Xiao (Professor, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
May 29, 2025
Start date
Jan 1, 2025
Primary completion
Jun 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
May 29, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion